ChitogenX Inc. (CHNXF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Kirkland, QC, Canada. The current CEO is Pierre Laurin.
CHNXF has IPO date of 2020-10-06, listed on the Other OTC, a market capitalization of $627.63K.
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.
